Your Global Leader in Stem Cell Market Research
Palo Alto, CA – I Peace, Inc., a global pioneer in iPSC (induced pluripotent stem cell) technology, proudly announces the launch of its personalized iPS cell production and longevity-focused rejuvenation therapies in the United States.
I Peace CEO Koji Tanabe spoke at the “Unlimited Health Conference,” a part of the Vitalist Bay, the biggest longevity event in the world, which is held in Berkeley, California. The event was held on April 5. [Read more…]
Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echo™-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]
Palo Alto, California, May 25, 2021 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up focusing on Nobel Prize-winning technology “induced pluripotent stem cells (iPSCs)” received a third-party certification as US FDA cGMP compliant for its manufacturing facility “Peace Engine Kyoto,” in Kyoto Japan. Peace Engine Kyoto is owned and managed by its sole subsidiary I Peace, Co. Ltd. The facility was awarded a permit in 2020 by Japan’s Ministry of Health, Labour, and Welfare to manufacture specific cell-based products. [Read more…]
SAN DIEGO, Calif., Jan. 05, 2021 — Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it will be collaborating with Dr. Rita Sattler at the Barrow Neurological Institute and Dr. Justin Ichida at the USC Keck School of Medicine on a grant awarded from the U.S. Department of Defense’s (“DOD”) Congressionally Directed Medical Research Programs (“CDMRP”) to evaluate its lead development candidate in ALS. [Read more…]
Numerous induced pluripotent stem cell (iPSC) derived therapeutics are now being studied in preclinical and clinical trials to investigate their potential to produce functional cells capable of replacing damaged or dysfunctional tissues.
It is important to note that the early clinical trials of iPSCs—and the majority of them today—do not involve the transplant of iPSCs into humans. Rather, they involve the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest. [Read more…]
